• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Alto Neuroscience Inc.

    11/14/24 7:00:29 AM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANRO alert in real time by email
    SC 13G 1 d873145dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO §240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO §240.13d-2

    (Amendment No.  )*

     

     

    Alto Neuroscience, Inc.

    (Name of Issuer)

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

    02157Q109

    (CUSIP Number)

    September 30, 2024

    (Date of Event which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 02157Q109    13G    Page 2 of 5 Pages

     

     1   

     NAME OF REPORTING PERSONS

     I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

     Amit Etkin

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     1,461,1301

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     1,461,1301

       8  

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     1,461,1301

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     5.4%2

    12  

     TYPE OF REPORTING PERSON*

     

     IN

     

    1 

    Consists of: (i) 1,205,465 shares of the Issuer’s common stock and (ii) 255,665 shares of common stock issuable upon the exercise of stock options within 60 days of September 30, 2024. Does not include 34,711 shares of the Issuer’s common stock issuable upon the vesting of an outstanding restricted stock unit which vests in two equal installments on September 1, 2025 and March 1, 2026, subject to the Reporting Person’s continuous service through such vesting date.

    2 

    This percentage is calculated based upon 26,970,168 outstanding shares of the Issuer’s common stock as of November 8, 2024, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 12, 2024.


    CUSIP No. 02157Q109    13G    Page 3 of 5 Pages

     

    Item 1.

     

    (a)

    Name of Issuer

    Alto Neuroscience, Inc.

     

    (b)

    Address of Issuer’s Principal Executive Offices

    650 Castro Street, Suite 450

    Mountain View, CA 94041

    Item 2.

     

    (a)

    Name of Person Filing

    Amit Etkin

     

    (b)

    Address of Principal Business Office or, if none, Residence

    c/o Alto Neuroscience, Inc.

    650 Castro Street, Suite 450

    Mountain View, CA 94041

     

    (c)

    Citizenship

    United States Citizen.

     

    (d)

    Title of Class of Securities

    Common Stock

     

    (e)

    CUSIP Number

    02157Q109

     

    Item 3.

    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: NOT APPLICABLE.

     

    (a)    ☐    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
    (b)    ☐    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c)    ☐    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d)    ☐    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
    (e)    ☐    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
    (f)    ☐    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
    (g)    ☐    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)    ☐    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)    ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)    ☐    A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
    (k)    ☐    Group, in accordance with §240.13d-1(b)(1)(ii)(K).


    CUSIP No. 02157Q109    13G    Page 4 of 5 Pages

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

    Item 4.

    Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a)

    Amount beneficially owned: See responses to Item 9 on the attached cover pages.

     

      (b)

    Percent of class: See the responses to Item 11 on the attached cover pages.

     

      (c)

    Number of shares as to which the person has:

     

      (i)

    Sole power to vote or to direct the vote – See the responses to Item 5 on the attached cover pages.

     

      (ii)

    Shared power to vote or to direct the vote – See the responses to Item 6 on the attached cover pages.

     

      (iii)

    Sole power to dispose or to direct the disposition of – See the responses to Item 7 on the attached cover pages.

     

      (iv)

    Shared power to dispose or to direct the disposition of – See the responses to Item 8 on the attached cover pages.

    Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

     

    Item 5.

    Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person

    Not Applicable

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

    Not Applicable

     

    Item 8.

    Identification and Classification of Members of the Group

    Not Applicable

     

    Item 9.

    Notice of Dissolution of Group

    Not Applicable

     

    Item 10.

    Certification

    Not Applicable.


    CUSIP No. 02157Q109    13G    Page 5 of 5 Pages

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    November 14, 2024

     

    /s/ Amit Etkin

    Amit Etkin
    Get the next $ANRO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANRO

    DatePrice TargetRatingAnalyst
    5/22/2026Outperform
    Wolfe Research
    5/5/2026$35.00Buy
    BofA Securities
    1/5/2026$30.00Buy
    Chardan Capital Markets
    11/17/2025Buy
    BTIG Research
    9/29/2025$15.00Buy
    Chardan Capital Markets
    10/23/2024$29.00 → $4.00Outperform → Neutral
    Wedbush
    10/23/2024Buy → Neutral
    Rodman & Renshaw
    9/3/2024$29.00Outperform
    Wedbush
    More analyst ratings

    $ANRO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF MEDICAL OFFICER Savitz Adam bought $190,833 worth of shares (15,000 units at $12.72) (SEC Form 4)

    4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

    7/11/24 4:15:04 PM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Smith Nicholas Conrad bought $100,628 worth of shares (6,150 units at $16.36), increasing direct ownership by 30% to 26,866 units (SEC Form 4)

    4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

    4/1/24 4:15:30 PM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANRO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors

    Miller brings deep neuropsychiatry drug development and value creation experience, having led R&D at Karuna Therapeutics through its $14 billion acquisition by Bristol Myers Squibb Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the appointment of Andrew Miller, Ph.D. to its Board of Directors, effective May 27, 2026. "We are thrilled to welcome Andrew to Alto's Board at a transformative time for the Company," said Amit Etkin, M.D., Ph.D., Founder and Chief Executive Officer of Alto Neuroscience. "Few leaders in our industry have done more to a

    5/28/26 8:03:00 AM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award

    Alto Neuroscience, Inc. (NYSE:ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today congratulates founder and CEO Amit Etkin, M.D., Ph.D. on receiving the Transformational Research Award from the VP&S Alumni Association at Columbia University Vagelos College of Physicians and Surgeons. This award honors VP&S alumni who are making transformational contributions to biomedical research within 25 years of graduation. "Having led global neuroscience R&D efforts for many years, I recognize that true transformation requires moving beyond the 'one-size-fits-all' model," said Husseini Manji, M.D., member of t

    5/15/26 8:27:00 AM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights

    – Phase 2b clinical trial of ALTO-207 in treatment-resistant depression (TRD) initiated – – New ALTO-101 analyses support significant effects on EEG markers of general cognition as well as a test of attention – – Closed $120 million PIPE in March 2026; cash balance of approximately $264 million expected to fund planned operations through 2029, including a potential NDA submission for ALTO-207 – Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the quarter ended March 31, 2026, and highlighted recent progress across its pipe

    5/13/26 7:03:00 AM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANRO
    SEC Filings

    View All

    Alto Neuroscience Inc. filed SEC Form 8-K: Leadership Update

    8-K - Alto Neuroscience, Inc. (0001999480) (Filer)

    5/28/26 8:18:14 AM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Alto Neuroscience Inc.

    SCHEDULE 13G/A - Alto Neuroscience, Inc. (0001999480) (Subject)

    5/15/26 5:05:16 PM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Alto Neuroscience Inc.

    SCHEDULE 13G/A - Alto Neuroscience, Inc. (0001999480) (Subject)

    5/15/26 4:11:23 PM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANRO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Miller Andrew Craig

    4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

    5/29/26 4:16:01 PM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Miller Andrew Craig

    3 - Alto Neuroscience, Inc. (0001999480) (Issuer)

    5/29/26 4:15:20 PM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRESIDENT AND CEO Etkin Amit gifted 400,000 shares, decreasing direct ownership by 32% to 833,949 units (SEC Form 4)

    4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

    5/15/26 5:06:10 PM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANRO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research initiated coverage on Alto Neuroscience

    Wolfe Research initiated coverage of Alto Neuroscience with a rating of Outperform

    5/22/26 9:38:37 AM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BofA Securities initiated coverage on Alto Neuroscience with a new price target

    BofA Securities initiated coverage of Alto Neuroscience with a rating of Buy and set a new price target of $35.00

    5/5/26 7:03:40 AM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chardan Capital Markets resumed coverage on Alto Neuroscience with a new price target

    Chardan Capital Markets resumed coverage of Alto Neuroscience with a rating of Buy and set a new price target of $30.00

    1/5/26 9:11:27 AM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANRO
    Leadership Updates

    Live Leadership Updates

    View All

    Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors

    Miller brings deep neuropsychiatry drug development and value creation experience, having led R&D at Karuna Therapeutics through its $14 billion acquisition by Bristol Myers Squibb Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the appointment of Andrew Miller, Ph.D. to its Board of Directors, effective May 27, 2026. "We are thrilled to welcome Andrew to Alto's Board at a transformative time for the Company," said Amit Etkin, M.D., Ph.D., Founder and Chief Executive Officer of Alto Neuroscience. "Few leaders in our industry have done more to a

    5/28/26 8:03:00 AM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.D., to Its Board of Directors

    Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the appointment of Raymond Sanchez, M.D., to its Board of Directors, effective August 12, 2025. Dr. Sanchez is a highly accomplished executive with a strong background in medicine and over 20 years of strategic experience in the life sciences industries. "We are delighted to welcome Ray to our Board of Directors as we continue advancing multiple clinical-stage precision psychiatry programs," said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto Neuroscience. "Ray brings an impress

    8/13/25 8:03:00 AM ET
    $ANRO
    $CERE
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Christopher Nixon Cox Named Chairman of High-Trend International Group

    SINGAPORE, March 13, 2025 /PRNewswire/ -- High-Trend International Group (NASDAQ:HTCO) (the "Company"), an international shipping company, today announced the appointment of Christopher Nixon Cox, as Chairman of the Company, effective immediately. Mr. Cox , a venture capitalist and advocate for socially impactful investing, will leverage his extensive expertise in global markets and sustainability to drive the Company's strategic growth in innovation-driven sectors. Mr. Jinyu Chang resigned as Chairman while remaining a director of the Company. The Company also named Mr. Bo Cui as its new Chief Legal Officer, underscoring its commitment to strengthening governance and global compliance amid

    3/13/25 9:00:00 AM ET
    $ANRO
    $HTCO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Marine Transportation
    Consumer Discretionary

    $ANRO
    Financials

    Live finance-specific insights

    View All

    Alto Neuroscience Reports Second Quarter 2025 Financial Results and Recent Business Highlights

    – Acquisition of potentially best-in-class dopamine agonist combination product candidates, including ALTO-207, expands precision psychiatry pipeline; guided by compelling PAX-D study results published in The Lancet Psychiatry – – ALTO-207 adds expected late-stage readout in treatment resistant depression within current cash runway; planned Phase 2b trial, designed to be a potentially pivotal study expected to initiate by mid-2026 – – Topline data expected from Phase 2 proof-of-concept (POC) trial of ALTO-101 in schizophrenia in the second half of 2025; Phase 2b topline data readouts include ALTO-300 in MDD expected mid-2026 followed by ALTO-100 in bipolar depression expected in the sec

    8/13/25 4:10:00 PM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alto Neuroscience Highlights Peer-Reviewed Publication of PAX-D Study in The Lancet Psychiatry Demonstrating Robust Clinical Effects of Pramipexole for Patients with Treatment-Resistant Depression

    –  Compelling PAX-D results guided Alto's acquisition of ALTO-207, designed to induce rapid antidepressant effects while mitigating dose-limiting adverse events of pramipexole – –  Alto plans to collaborate with National Health Service, PAX-D clinical sites for the planned Phase 2b trial of ALTO-207, designed to be a potentially pivotal study; trial expected to initiate by mid-2026 – Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today highlighted The Lancet Psychiatry publication of data from the PAX-D study evaluating pramipexole in patients with treatment-r

    6/30/25 8:03:00 AM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway

    – ALTO-207 (fka CTC-501) is a fixed-dose combination of pramipexole and ondansetron designed to induce rapid antidepressant effects while mitigating dose-limiting adverse events of pramipexole – – Alto has generated proprietary insights on dopamine biomarkers in depression suggesting that direct dopamine receptor activation with ALTO-207 has the potential to be a differentiated therapeutic approach for treatment resistant depression (TRD) – – CTC-501 met primary and secondary endpoints in a completed Phase 2a study in MDD, demonstrating significantly greater improvements on MADRS compared to placebo (Week 8 Cohen's d = 1.1, p<0.05) – – Alto expects to initiate a Phase 2b trial, design

    6/3/25 6:03:00 AM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANRO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Alto Neuroscience Inc.

    SC 13G/A - Alto Neuroscience, Inc. (0001999480) (Subject)

    11/14/24 5:46:11 PM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Alto Neuroscience Inc.

    SC 13G - Alto Neuroscience, Inc. (0001999480) (Subject)

    11/14/24 7:00:29 AM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Alto Neuroscience Inc.

    SC 13G - Alto Neuroscience, Inc. (0001999480) (Subject)

    11/12/24 9:50:14 AM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care